Sartorius Stedim Biotech Acquires Majority Stake in AllPure Technologies

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-07-2014
Volume 10
Issue 5

Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.

Sartorius Stedim Biotech has signed a contract to acquire the majority stake in the US start-up, AllPure Technologies LLC. The privately owned company based in New Oxford, PA, has been in operation for four years, and earned revenue of approximately $3 million in 2013 with 25 employees. AllPure specializes in single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.

Source: Sartorius Stedim Biotech

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content